Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ark Biosciences
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.
Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.
Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.